| Name | Alemtuzumab |
|---|
| Description | Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52, a glycoprotein expressed on the surface of most lymphoid, and to a lesser extent, myeloid cell types. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes[1][2]. |
|---|---|
| Related Catalog | |
| References |
| No Any Chemical & Physical Properties |